spin-outs
in 2018
Spin-outs
University of Nottingham Innovation Park
We are a wholly-owned subsidiary of the University based in the Ingenuity Centre within the University of Nottingham Innovation Park.
Nottingham Technology Ventures also manages the £5 million Nottingham Invention Fund, which invests in University spin-out companies to support their development and growth.
Sectors
Our board
Dr Andrew Naylor
Professor Dame Jessica Corner
Dr Susan Huxtable
Professor Andy Long
Margaret Monckton
Exits
It is University policy to sell the majority of its shares in spin-out companies when an appropriate opportunity arises. The University uses the proceeds to support teaching and research.
Our Spin-outs on Twitter
EventMAP facilitates the return to the office. http://ow.ly/kuUr50GehTM
It's #WorldEnergyStorageDay where we celebrate the contribution of energy storage in enabling a clean energy future. Check out the latest edition of our Energy Storage Landscape to keep updated with the ever-changing industry 🌎
Energy Storage Landscape
Check out the latest edition of our Energy Storage Landscape to keep updated with the ever-changing industry.
cheesecakeenergy.com
TextureJet has moved! We have moved to a new 4500sqft facility in Bulwell, Notts. After outgrowing our previous 1000sqft facility within 18 months, we now have increased both operations and office spaces to support our long-term growth.
#surfacefinishing #highvaluemanufacturing
Exonate are delighted to announce that our COO Dr Loic Lhuillier will be taking part in the Panel Session ’How to negotiate Big Pharma’ 9.30 at BioForward 2021, which provides R&D business leaders with knowledge and skills required to achieve commercial success.
#lifesciences
Exonate are hiring a research scientist in drug discovery on a 4 month position to join exciting projects in RNA splicing therapeutics. Great opportunity for a PhD or equivalent lab experience with molecular biology skills. Apply here https://indeedhi.re/3nVhBMi
Vision impairment is formally defined as best-corrected visual acuity of 20/70 or worse in both eyes.
Using human Amniotic Membrane-Derived Dry Matrix (AMDDM) in the form of Omnigen® delivered with OmniLenz®, 86% of patients with PED vision remained stable or improved.
We're donating some seed to @Stonebridgecit1, it's a great place to come and feed the animals as well as see the fantastic gardens (there's a playpark for the kiddies too!)
A clinical trial focusing on the use of Human Amniotic Membrane-derived Dry as a management option for Persistent Corneal Defect saw 66.6% of aniridia patients had complete or partial healing.
We are currently on site at Young Epilepsy in Surrey installing our second commercial OPM-MEG system!
More pictures to follow over the coming weeks.
@youngepilepsy @UniofNottingham @Sensors_QTHub #EpilepsyResearch
Learn more at:
https://www.cercamagnetics.com/
